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ABSTRACT
Human proximal tubular epithelial cells (PTEC) of the kidney are known to respond to and
mediate the disease process in a wide range of kidney diseases, yet their exosomal production
and exosome molecular cargo remain a mystery. Here we investigate, for the first time, the
production and molecular content of exosomes derived from primary human PTEC cultured
under normal and diseased conditions representing a spectrum of in vivo disease severity from
early inflammation, experienced in multiple initial kidney disease states, through to hypoxia,
frequently seen in late stage chronic kidney disease (CKD) due to fibrosis and vascular compro-
mise. We demonstrate a rapid reproducible methodology for the purification of PTEC-derived
exosomes, identify increased numbers of exosomes from disease-state cultures and identify
differential expression levels of both known and unique miRNA and protein species from exo-
somes derived from different disease-culture conditions. The validity of our approach is sup-
ported by the identification of miRNA, proteins and pathways with known CKD associations,
providing a rationale to further evaluate these novel and known pathways as targets for
therapeutic intervention.
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Introduction
Extracellular vesicles (EVs) have been collectively
recognised as fundamental components of intercellular
communication that can be broadly grouped into three
main classes (exosomes, microvesicles and apoptotic
bodies) according to their biogenesis, size and molecu-
lar cargo. Of these, exosomes are produced within the
multivesicular endosome compartments of the cell and
are secreted when these compartments fuse with the
plasma membrane [1]. They are characterised on their
size distribution (50–120 nm) and expression of certain
tetraspanins including CD9, CD63 and CD81 [2]. This
specialised subset of EVs is secreted by many different
cell types in a constitutive process [3], but their num-
bers have also been shown to be increased in oxidative
stress and hypoxia [4,5]. They have been demonstrated
to play a major role in cell-to-cell communication and
carry a cargo of specific bioactive proteins, lipids,
mRNA and miRNA to facilitate this communication.
Over recent years exosomes and their specific
molecular cargo have also been implicated as both
positive and negative disease progression mediators,
prompting much investigation into their role as novel
biomarkers and potential therapeutic targets [6,7].
Renal researchers have also reported exosome produc-
tion from the kidney and it is emerging that they play a
role in embryonic renal development [8], intra-tubular
cellular communication [9], tumour development [10],
disease progression [11] and disease control [12]. Urinary
exosomes derived from the kidney also offer the potential
for novel non-invasive biomarkers of specific kidney dis-
eases and the monitoring of acute and chronic kidney
disease (CKD) [13–16]. A number of research groups
have purified exosomes from urine of people with dis-
eased and normal kidneys and characterised their
miRNA and protein content using gene array and mass
spectrophotometry in efforts to identify suitable molecu-
lar candidates. However, most of these studies are unable
to define the cellular source of urinary exosomes as they
may originate from any cell type lining the urinary space
from podocytes through proximal and distal renal
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epithelial cells down to urethral–bladder epithelial cells.
In addition, glomerular damage that occurs in numerous
kidney diseases may even allow the filtering of exosomes
direct from the circulating plasma.
Proximal tubular epithelial cells (PTEC) of the
kidney are known to respond to and mediate the
disease process in a wide range of kidney diseases
[13] and we have demonstrated that they may play a
regulatory role during the initial acute injury phase,
characterised by inflammation [14,15], but a patho-
genic role in the developed chronic fibrotic disease
state, characterised by hypoxia [16,17]. PTEC are
uniquely sensitive to the hypoxic conditions that pre-
vail in renal fibrosis, a common pathological finding
in multiple renal diseases. These perturbed PTEC
undergo multiple molecular and cellular changes
[17,18] and it seems very likely that such perturba-
tion would also induce changes within their exosome
profile. Minimal work using mouse models and
transformed human PTEC cell lines has demon-
strated that PTEC-derived exosomes may also play a
role in disease progression [11]. However, to our
knowledge, no one has directly characterised exo-
somes from human primary PTEC under normal or
diseased conditions. To address this issue we purified
and characterised exosomes from primary human
PTEC that were cultured under normal conditions
and under inflammatory and hypoxic conditions to
mimic the acute and chronic conditions likely to be
encountered by these cells in vivo.
Our results demonstrate that exosomes are readily
purified from human primary PTEC using a reprodu-
cible commercially available kit, that production of
exosomes are elevated under inflammatory and
hypoxic states and that these “perturbed” exosomes
contain condition-specific miRNA species and proteins
linked to renal pathological processes.
Materials and methods
Isolation and culture of human primary PTEC
Renal cortical tissue was obtained with informed
patient consent from the macroscopically/microscopi-
cally healthy portion of tumour nephrectomies, follow-
ing approval by the Royal Brisbane and Women’s
Hospital Human Research Ethics Committee (2006/
072). PTEC were purified following the method of
Glynne and Evans [19] and cultured in defined med-
ium (DM) as previously described [20]. All PTEC
underwent a maximum of three passages prior to use
in this study.
Activation of human primary PTEC to mimic the
disease state
PTEC were cultured in DM to 70–80% confluence and
then further cultured for 72 h in fresh DM for normal
control PTEC, in fresh DM in the presence of IFN-γ
(100 ng/ml) and TNF-α (20 ng/ml) (both from R&D
Systems, Minnesota, USA) for inflammatory PTEC and
in fresh DM (pre-treated to hypoxia (1% O2 for 24 h)
and then cultured under 1% O2 hypoxia for 72 h in an
Invivo2 1000 Hypoxia Workstation (Ruskinn Laftec,
Bayswater North, Victoria, Australia). Cell culture
supernatants were harvested for exosome purification
and subsequent analysis, whilst PTEC were harvested
for HLA-DR and PD-L1 expression by flow cytometry
and protein extraction for HIF-1α expression by
Western blotting where required.
Exosome purification
Ultracentrifugation/density gradient (UC/DG)
PTEC cell culture medium (75 ml) was centrifuged at
300g for 10 mins at 4°C and filtered through a
0.22 µm filter (Merck Millipore, Bayswater, Victoria,
Australia) to remove contaminating apoptotic bodies
and cell debris. The clarified supernatant was then
centrifuged at 100,000g overnight at 4°C using a
SW31Ti rotor to pellet exosomes. Each crude exo-
some pellet was re-suspended in 1 ml of ice-cold PBS,
pooled and re-centrifuged on a TLA100.3 rotor at
100,000g for 1 h at 4°C. Pellets were then washed a
further two times at 100,000g for 30 mins at 4°C and
re-solubilised in 200 μl PBS. This sample was applied
to a 5–40% Iodixanol gradient (in 0.25 M sucrose
10 mM Tris pH 7.2) and centrifuged at 100,000g for
18 h at 4°C. One millilitre fractions were harvested
from the gradient, the absorbance of each fraction
measured at 244 nm and fraction 1.12–1.24 g/ml
Iodixanol (calculated via the Beer–Lambert law) con-
taining the exosomes was then washed and ultracen-
trifuged at 100,000g for 2 h at 4°C, followed by a final
wash at 100,000g for 30 mins and resuspension in
20 μl PBS.
Commercial kit purification
Exosomes from PTEC cell culture medium (75 ml),
from the same pool used in the UC/DG experiments,
were purified using the exoEasy Maxi Kit (Qiagen,
Melbourne, Vic. Australia) as per the manufacturer
instructions. Following the final step exosomes were
ultracentrifuged at 100,000g for 30 mins at 4°C and
re-solubilised in 20 μl PBS.
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Exosome purification from donor PTEC cultured
under normal and disease conditions
Six separate donor PTEC samples were cultured under
normal, inflammatory and hypoxic conditions for
3 days. Exosomes were purified from 180 ml of PTEC
culture supernatants, from each culture condition,
using the exoEasy Maxi Kit from Qiagen. The concen-
tration and size distribution of particles was analysed
with tuneable resistive pulse sensing (TRPS) (qNano,
Izon Science Ltd. Christchurch, New Zealand) follow-
ing the method of Lobb et al. [21]. Briefly, a NP100
nanopore was used at a 45 mm stretch and the con-
centration of particles was standardised using multi-
pressure calibration with 70 nm carboxylated polystyr-
ene beads at a concentration of 1.5 × 1011 particles/ml.
Electron microscopy
Ten microlitres of exosome suspension were applied on
a Formvar-coated and carbon stabilised copper grid
and stained with 1% aqueous uranyl acetate. Samples
were examined using a JEM 1011 transmission electron
microscope operated at 80 kV and equipped with a
digital camera.
Flow cytometry
For surface HLA-DR and PD-L1 expression, single cell
suspensions were initially stained with LIVE/DEAD®
Fixable Near-IR Dead Cell Stain Kit (Invitrogen) to
allow exclusion of non-viable cells. Cells were then
stained on ice for 30 min with combinations of test
(0.25 μg per antibody) or isotype-matched control anti-
bodies in cold FACS buffer [0.5% BSA (Sigma, St
Louis, MO, USA) and 0.02% sodium azide (Sigma) in
PBS]. Anti-HLA-DR-APC (clone G46-6) was from BD
Biosciences (San Jose, CA, USA) and anti-PD-L1-
BV421 (clone 29E.2A3) was from Biolegend (San
Diego, CA, USA). Cell acquisition was performed on
an LSR Fortessa (BD, San Jose, CA, USA) and data
analysed with FlowJo software (TreeStar, Ashland,
OR, USA).
Western blotting
Antibodies (Ab) used in western blot (WB) included
CD9 (Clone Ts9, Invitrogen/Thermo Fisher Scientific,
Carlsbad, CA, USA), CD63 (Clone Ts63, Invitrogen/
Thermo Fisher Scientific), CD81 (Clone M38,
Invitrogen/Thermo Fisher Scientific), HIF-α (Clone
54/HIF-1α, BD Biosciences), calnexin (Clone AF18,
Santa Cruz, Dallas, Texas. USA) and beta-tubulin
(Cat. No. ab6046, Abcam, Melbourne, Vic. Australia).
Cells and exosomes were lysed with RIPA/PI buffer
and protein content determined using the BCA protein
assay (Pierce/Thermo Fisher Scientific). PAGE was
undertaken using standard reagents from Invitrogen.
Samples were denatured for 5 mins at 95°C, loaded
onto Bolt™ 4–12% Bis-Tris Plus Gels, run at 165 V for
38 mins and transferred to nitrocellulose membrane at
10 V for 60 mins. Membranes were probed with pri-
mary Ab overnight at 4°C, blocked for 1 h at RT using
Odyssey® blocking buffer (LI COR, Lincoln, NE USA)
and visualised with IRDye 800CW Goat anti-Mouse
(Millennium Science, Mulgrave, Vic. Australia) or
IRDye 680LT Goat anti-Rabbit (Millennium Science)
using the Odyssey CLX (LI COR) and Image Studio 2.0
software (LI COR).
miRNA analysis
RNA was isolated using a Qiagen RNeasy Kit. The manu-
facturer’s protocol was varied by replacing washing Buffer
RW1 with Buffer RWT which prevents the miRNA from
being washed off the column prior to elution. RNA QC
was performed on a BiOptics QSep and a Thermofisher
NanoDrop 2000; 500 ng of exosome RNA were then used
to create an RNAseq library using the NEBNext Small
RNA Library Prep Kit (NEB), and sequenced at 1 × 36bp
on an Illumina NextSeq 500. FastQ files were aligned to a
reference consisting of pre-miRNAhairpins frommiRBase
v21 (http://miRBase.org). Alignment was performed using
RNA-STAR v2.3.0 (reference: http://bioinformatics.oxford
journals.org/content/29/1/15.full) using the following
parameters: “–runThreadN 16 – outSAMattributes All –
outFilterMultimapNmax 1”, and all other parameters at
default. Differential miRNA expression was calculated
using the R Bioconductor package edgeR. MiRNAs with
less than 10 total counts were filtered, and the libraries
were normalised using the TMM method. MiRNAs were
considered as statistically significantly differentially
expressed when the log2 fold change was greater than 1,
and the adjusted p-value (accounting for multiple testing
false discovery rate (FDR) correction) was less than 0.05.
Reduction, alkylation and tryptic digest of exosome
proteins for tandem mass spectrometry
Purified exosomes were lysed with a 1% SDS, 10 mM
CHAPS, 5 mM MgCl2 in 100 mM TEAB for 30 min
under agitation at 4°C and the total exosomal protein
content was determined for each samples by Pierce
BCA protein assay (Thermo Scientific). Exosome pro-
teins were then prepared for mass spectroscopy using a
modified FASP protocol as previously described [22].
Briefly, proteins were reduced, alkylated and digested
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on a 30 kDa molecular weight cut-off membrane in 96-
well plates. Recovered peptides were dried in a speed
vacuum for 4 h at 45°C.
Tandem mass spectrometry
Tryptic peptides were solubilised in a solution of 0.1%
trifluoroacetic acid (TFA), desalted on ZipTip C18
pipette tips (Millipore) and spiked with iRT calibrant
(Biognosys, Zurich, Switzerland) for use in spectral
library generation [23]. Peptides were then chromato-
graphically separated before tandem mass spectrometry
in IDA mode on an AB Sciex 5600+ TripleTOF as
previously described [24]. For SWATH acquisition,
the mass spectrometer was operated under the same
conditions as for the DDA experiments and a rolling
collision energy method was used to fragment all ions
in a set of 26 sequential overlapping windows of 25
AMU over a mass range coverage of 350–1000 (m/z).
An accumulation time of 100 ms was used for each
fragment ion scan resulting in a total cycle time of
2.9 s. Data was acquired and processed using Analyst
TF 1.7 software (AB SCIEX).
Spectral searches and library generation from DDA
files
Spectral searches of processed LC-MS/MS data were
performed using ProteinPilot v4.5 (AB SCIEX) using
the Paragon algorithm (version 4.5.0.0). Background
correction was used and biological modifications spe-
cified as an ID focus. The detected protein threshold
was set as 0.5 and the FDR was calculated using
searches against a decoy database comprised of
reversed sequences. Searches were conducted against
the UniProt human reference proteome set comprising
70,236 protein sequences (downloaded 30 March
2016). For spectral library generation X! Tandem
Jackhammer TPP (2013.06.15.1) was used to search
all DDA files against a target/decoy version of the
UniProt human reference proteome set additionally
containing a reversed version of each sequence and
the iRT sequences as previously described [25].
OpenSwath was used to conduct searches against the
spectral library using a FDR below 0.1% as previously
described [23]. Feature alignment was performed using
the transition of identification confidence algorithm
(https://pypi.python.org/pypi/msproteomicstools) and
the R package SWATH2stats [26] was used to filter
low scoring peak groups and remove proteins with
less than two associated peptides. MSstats [27] was
used to generate differential expression values with an
adjusted p-value ≤ 0.05 considered significant.
Pathway analysis
Annotations for significantly dysregulated proteins
were obtained using the Qiagen ingenuity pathway
analysis (IPA) program following the core analysis
workflow using standard parameters: stringent filter
for molecules and relationship and no protein fold
change cut-off applied. Readouts included the
“Disease and Biological Function”, “Tox” clustering
and “Networks” pathway analyses.
Results
Exosomes purified from normal primary human
PTEC
We undertook initial experiments to compare the
purity and recovery rates of exosomes, from the cell
culture media of PTEC cultured under normal condi-
tions, using ultracentrifugation-density gradient (UC-
DG) purification versus a rapid commercial kit pro-
cedure. Western Blotting of proteins extracted from
both populations of exosomes demonstrated the pre-
sence of the canonical exosome protein CD9 and the
absence of the endoplasmic reticulum protein
Calnexin, confirming their exosome purity (Figure 1
(a)). Using TRPS, we obtained a large increase in
numbers of exosomes using the standardised quality
controlled commercial kit compared to the UC-DG
methodology (Figure 1(b)). However, both popula-
tions demonstrated the same exosomal size profile of
50–120 nm (Figure 1(c)). All subsequent exosome
purifications were undertaken using the commercial
kit methodology.
Inflammatory and hypoxic markers on PTEC
cultured under disease conditions
To ensure our primary human PTEC responded appro-
priately to our inflammatory and hypoxic culture condi-
tions we monitored their expression of human leucocyte
antigen DR (HLA-DR) and programmed death-ligand 1
(PD-L1) by flow cytometry and hypoxia inducible factor
1α (HIF-1α) by Western blotting (WB). As we have pre-
viously published [15], PTEC up-regulated both HLA-DR
and PD-L1 in response to inflammatory cytokine stimula-
tion, but demonstrated no up-regulation of these surface
molecules in response to hypoxia (Figure 2(a)). As
expected there was a significant up-regulation of HIF-1α
within PTEC cultured under hypoxic conditions but no
increase of this molecule in PTEC cultured under inflam-
matory conditions (Figure 2(b)).
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Exosomes purified from primary human PTEC
cultured under normal versus disease conditions
PTEC cultured under inflammatory conditions pro-
duced on average 60% more exosomes than those
cultured under normal control conditions whilst those
cultured under hypoxic conditions produced on aver-
age 80% more exosomes than those cultured under
normal control conditions (Figure 3(a)). There were
Figure 1. Exosomes purified from primary human PTEC cultured under normal conditions using ultracentrifugation/density gradient
purification (UC-DG) and commercial kit purification (Kit) demonstrate comparable purity. (a) PTEC exosomes from both purification
methodologies express CD9 but not calnexin. Western blot analysis of whole PTEC/exosome lysate (5 µg total protein per sample).
(b) Numbers of exosomes purified from equivalent cell culture volumes. One representative of two PTEC donor experiments. (c)
Equivalent size distribution of exosomes produced with the two methodologies; analysed with TRPS (qNano, Izon Science Ltd.
Christchurch, New Zealand) using a NP100 nanopore at a 45 mm stretch. One representative of two PTEC donor experiments.
Figure 2. Primary human PTEC express inflammation markers and HIF-1α under inflammatory (IFN-γ (100 ng/ml) and TNF-α (20 ng/
ml)) and hypoxic (1% O2) culture conditions, respectively. (a) Flow cytometry profiles demonstrate PTEC up-regulate HLA-DR and
PD-L1 under inflammatory culture conditions (thick line, unfilled) but show no up-regulation of these molecules under hypoxia (thin
line, unfilled). Dashed line, unfilled is normal culture conditions and grey filled is isotype control. One representative of two PTEC
donor experiments. (b) Western blot analysis of whole PTEC cell lysate (5 µg total protein) demonstrate HIF-1α expression under
hypoxic culture conditions but no HIF-1α expression under normal or inflammatory culture conditions. One representative of two
PTEC donor experiments.
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no significant differences in the size distribution of
these 3 exosome populations (Figure 3(b)). In line
with this quantitative data, we also observed more
exosomes from equivalent cell culture volumes under
disease conditions by electron microscopy. However,
all 3 populations displayed the same exosomal cup-
shaped morphology (Figure 3(c)). Analysis of these 3
exosome populations by WB for CD9, CD63 and CD81
expression, using equivalent ml of supernatant input,
indicated increasing CD9 expression from normal <
inflammation < hypoxia, whilst CD63 and CD81
expression increased normal < hypoxia/inflammation
(Figure 4).
miRNA analysis of exosomes cultured under
normal versus disease conditions
We next examined miRNA content of purified exo-
somes using NextSeq 500 sequencing. When miRNAs
with less than 10 total counts were filtered, and the
libraries were normalised using the TMM method, we
identified a total of 59 miRNA within exosomes pro-
duced by our six donors. Analysis of these miRNA
using high-stringency FDR analysis identified five
miRNA species that were significantly different
between the inflammation versus the normal control
culture group, three miRNA species that were
significantly different between the hypoxia versus the
normal control culture group and three miRNA species
that were significantly different between the hypoxia
versus the inflammation culture group (Table 1). One
miRNA species, hsa-miR-7641-2-3p, appeared across
all three culture groups with a minus log2 fold change
of 2.13 in inflammation vs normal (FDR 4.12 × 10−9),
3.53 in hypoxia vs normal (FDR 1.67 × 10–15) and 1.40
in hypoxia vs inflammation (FDR 0.045).
Three of the four miRNA species that were signifi-
cantly elevated in the inflammation vs the normal
control group (hsa-miR-200a, hsa-miR-222 and hsa-
miR-204) and one of the two miRNA species that was
significantly elevated in the hypoxia vs inflammation
culture group (hsa-miR-375) have been previously
implicated in one or more studies as players in renal
disease (see discussion).
Proteomic analysis of exosomes cultured under
normal versus disease conditions
Analysis of the protein content of exosomes across all
six donors identified a total of 536 proteins each con-
taining at least two significant peptides (>95% prob-
ability with at least one peptide unique to the protein)
at a FDR < 0.05. Of these, 212 were found in exosomes
derived from all three culture conditions; 31 were
Figure 3. Primary human PTEC produce more exosomes under disease culture conditions but with comparable morphology. (a)
Exosome numbers produced by equivalent cell culture volumes under normal and disease (inflammation and hypoxia) culture
conditions. All exosomes purified using the Kit methodology. Results represent mean ± SEM of six individual PTEC donor
experiments. *p < 0.05 by one-way analysis of variance with Bonferroni’s multiple-comparison test. (b) Equivalent size distribution
of exosomes derived from primary human PTEC under normal and disease conditions; analysed with TRPS (qNano, Izon Science Ltd.
Christchurch, New Zealand) using a NP100 nanopore at a 45 mm stretch. All exosomes purified using the Kit methodology. Results
represent mean ± SEM of six individual PTEC donor experiments. (c) Electron microscopy images of exosomes purified from PTEC
cultured under normal and disease conditions. Scale bars = 100 nm. All exosomes purified using the Kit methodology.
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shared between exosomes derived from normal and
inflammation culture conditions; 62 were shared
between exosomes derived from normal and hypoxic
culture conditions; and 18 were shared between exo-
somes derived from inflammation and hypoxic culture
conditions. Of the unique proteins, 88 were unique to
exosomes produced under normal control culture con-
ditions, 72 to exosomes produced under inflammatory
culture conditions and 53 to exosomes produced under
hypoxic culture conditions (Figure 5).
A comparison of exosome protein expression levels
across the culture condition groups was performed
using SWATH/MS. A spectral library was constructed
composed of the spectra used to identify the 536 pro-
teins described above and total exosome protein from
each of the different culture conditions were subjected
to SWATH analysis; relative expression levels were
then calculated using OpenSwath and MSstats. Seven
proteins were identified as significantly down-regulated
and five as significantly up-regulated between inflam-
mation versus normal; one and four proteins, respec-
tively, between hypoxia versus normal; and one and six
proteins, respectively, between hypoxia versus inflam-
mation (Table 2). Many of these individual proteins
have described roles in pathways involved in renal
fibrosis including extracellular matrix deposition (lami-
nin, plectin, fibronectin, tenascin, heparan sulfate) and
protein binding/cell junction assembly (plectin,
T-complex protein, thrombospondin-1, filamin-A),
providing a possible link between extracellular signal-
ling and this pathophysiological process.
To further investigate the function of the proteins
that were significantly differentially expressed between
the normal and diseased culture conditions we con-
ducted unbiased pathway analyses using the “Disease
and Biological Function” clustering function of the IPA
program with a stringent p-value cut-off of < 1e-4. Two
Figure 4. Primary human PTEC cultured under disease condi-
tions produce greater numbers of exosomes – defined by CD9/
CD63/CD81 content. Western blot of whole exosome lysates
(5 µg total protein) following purification of exosomes from
equivalent cell culture volumes under normal and disease
(inflammation and hypoxia) culture conditions. Blots were
probed with anti-CD9 (top gel), anti-CD63 (middle gel) and
anti-CD81 (bottom gel). All exosomes purified using the Kit
methodology.
Table 1. Significantly differentially expressed exosomal miRNA.
MicroRNA
Log2 fold
change
FDR-adjusted
p-value
Inflammation vs normal
hsa-miR-7641-2-3p −2.13 4.12E-09
hsa-miR-4419a-5p 1.70 0.029
hsa-miR-200a-3p 1.13 0.049
hsa-miR-222-3p 1.03 0.031
hsa-miR-204-5p 2.51 0.036
Hypoxia vs normal
hsa-miR-7641-2-3p −3.53 1.67E-15
hsa-miR-3182-5p 2.30 0.002
hsa-miR-4448-3p 1.82 0.018
Hypoxia vs inflammation
hsa-miR-7641-2-3p −1.40 0.045
hsa-miR-3613-5p 2.13 0.043
hsa-miR-375-3p 1.83 0.012
Figure 5. Exosomes purified from human primary PTEC cul-
tured under normal and disease conditions contain both shared
and unique proteins. Total numbers of identified proteins
(bold) and percentage of total identified proteins (in brackets)
for each individual culture condition are presented.
JOURNAL OF EXTRACELLULAR VESICLES 7
renal associated pathways were identified: (i) renal and
urological diseases, and (ii) renal and urological sys-
tems development and function. Additionally, as
expected, a number of pathways intimately linked
with inflammatory and hypoxic processes were also
identified, including (i) inflammatory response, (ii)
inflammatory disease, (iii) cellular compromise, (iv)
cell to cell signalling, (v) immune cell trafficking, (vi)
cell death and survival, (vii) cellular function and
maintenance, (viii) cellular compromise and (ix) cell-
mediated immune response.
Mapping these same proteins within the “Tox
Function” of IPA, which maps pathways upon tox-
icological phenotypes and clinical pathology end-
points, identified numerous renal-associated path-
ways that are known to occur in CKD, including (i)
renal fibrosis, (ii) renal nephritis, (iii) renal inflam-
mation, (iv) renal dysfunction, (v) renal tubular
injury, (vi) renal damage and (vii) kidney failure.
Two specific examples from the inflammation versus
normal culture group are C3, FN1 and THBS1 asso-
ciating with “Damage of Renal Tubules” (2.13E-6),
and C3, TF and THBS1 associating with “Renal
Impairment” (4.37E-4).
Interrogating the “Networks” function of IPA with
our significantly expressed proteins highlighted a cell
to cell signalling/inflammatory response pathway
involving 11 out of the 12 proteins in the inflammation
versus normal culture group (Figure 6) and a cellular
assembly and organisation/cell morphology pathway
involving 11 out of 17 proteins in the hypoxic culture
group versus inflammation/normal culture condition
groups (Figure 7). These network pathway findings
confirm the validity of our experimental approach.
Discussion
PTEC play a central role in the development of fibrosis,
a common end stage result of many renal diseases,
irrespective of aetiology. Exosomes, and their cargo of
specific bioactive molecules, produced by the kidney,
have been implicated in numerous disease pathways.
Despite this, until now, no one has characterised the
production of exosomes from human primary PTEC
under normal or diseased conditions. In our study, we
demonstrate for the first time, that purified primary
human PTEC produce increased numbers of exosomes
under disease conditions and that these exosomes con-
tain both miRNA and protein specific signatures that
differ from those derived from PTEC cultured under
normal control conditions.
We initially compared the purification methods of
UC/DG and a commercially available kit, the Qiagen
exoEasy Maxi Kit, to obtain purified exosome prepara-
tions. We undertook this comparison because our
initial work with exosome purification using UC/DG
methodology demonstrated that this procedure was
extremely laborious and time consuming and prone
to technical problems including breakage of UC tubes
and DG dissociation leading to exosome sample loss.
The use of the commercial kit held the benefit of a
simple, time efficient methodology that was reproduci-
ble and quality controlled. Our results clearly demon-
strate that exosomes purified with the kit were of
equivalent quality to those produced using UC/DG
and also resulted in a much greater yield of exosomes,
probably due to the large reduction in the number of
centrifugation steps the samples were subjected to.
We examined exosome production from the super-
natants of six separate PTEC donors cultured under
three separate conditions to replicate normal control
culture conditions, inflammatory disease culture con-
ditions and hypoxic disease culture conditions.
Supporting the findings of others who have reported
increased exosome production from breast cancer cell
Table 2. Significantly differentially expressed exosomal proteins.
Protein
Gene
symbol
Log2
fold
change
FDR-
adjusted
p-value
Inflammation vs normal
Laminin subunit alpha-3 LAMA3 −1.07 0.007
T-complex protein CCT8 −0.83 0.008
Plectin PLEC −0.76 0.013
Complement C3 C3 −0.68 0.019
Fibronectin FN1 −0.67 0.041
Cytoplasmic dynein 1, heavy chain 1 DYNC1H1 −0.60 0.007
Fatty acid synthase FASN −0.51 0.015
Serotransferrin TF 0.56 0.007
Lysyl oxidase homologue 2 LOXL2 0.85 0.031
Heparan sulfate proteoglycan core
protein
HSPG2 1.12 0.002
Thrombospondin-1 THBS1 1.59 0.007
Laminin subunit alpha-4 LAMA4 1.73 3.53E-4
Hypoxia vs normal
Filamin-A FLNA −0.51 0.036
Heparan sulfate proteoglycan core
protein
HSPG2 0.71 0.036
Complement C3 CO3 0.87 0.036
Tenascin TNC 0.98 0.036
Galectin-3-binding protein LGALS3BP 1.24 0.036
Hypoxia vs inflammation
Tubulin beta-4B chain TUBB4B −0.67 0.037
Eukaryotic translation initiation factor 3,
subunit C
EIF3C 0.50 0.015
T-complex protein (Renal carcinoma
Ag)
CCT8 0.57 0.043
T-complex protein 1, subunit beta CCT2 0.99 0.023
Tenascin TNC 1.10 0.023
Galectin-3-binding protein LGALS3BP 1.81 0.002
Laminin subunit alpha-1 LAMA1 2.52 0.048
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lines [5], mesenchymal stem cells [28] and a mouse
renal cell line (MCT) [11] under hypoxic and stressed
culture conditions, we also identified an increase of
exosome secretion under diseased conditions from pri-
mary human PTEC. These increases were confirmed by
both particle number defined by TRPS and the relative
abundance of CD9, CD63 and CD81 assessed by WB,
normalised to equivalent ml of supernatant.
Interestingly, despite this finding that PTEC secrete
increased numbers of exosomes under disease condi-
tions and the fact that PTEC form a major cell popula-
tion lining the urinary space, no definitive report has
described increased numbers of exosomes in urine
from renal disease patients.
Applying high stringency statistical analysis and
FDR to our miRNA data, we have identified different
miRNA species expressed in exosomes between our
normal and disease culture groups. One miRNA spe-
cies of particular interest is hsa-miR-7641-2-3p. This
miRNA was identified as the most significantly down-
regulated of all the miRNA species and has been iden-
tified as negatively regulating the expression of CXCL1
in human embryonic stem cells [29]. Yoo et al. [29]
clearly demonstrated CXCL1 as the target gene for this
miRNA and showed that miR-7641 decreased the
expression of both CXCL1 mRNA levels and protein
levels. There are no other reports of this miRNA-
CXCL1 interaction within the scientific literature but
CXCL1 is the primary chemokine responsible for neu-
trophil chemotaxis during early inflammation [30,31].
It is therefore tempting to hypothesise that the signifi-
cant down-regulation of miR-7641 within inflamma-
tory cultured PTEC exosomes represents a novel
pathway to increase CXCL1 expression and subsequent
neutrophil influx into the kidney as a first line of
defence against the inflammatory response.
Four further miRNA species were identified as
being significantly up-regulated in the exosomes of
PTEC from inflammatory cultures compared to con-
trols. Of these, three (hsa-miR-200a, hsa-miR-222
Figure 6. Eleven out of the 12 significantly differentially expressed exosomal proteins, derived from the inflammatory culture
conditions compared to the normal culture conditions, associate with a cell to cell signalling/inflammatory response pathway
identified by the Networks function of IPA. The colour intensity indicates amount of up-regulation within the network. Proteins
highlighted in bold within the data table are the 11 significantly differentially expressed exosomal proteins.
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and hsa-miR-204) have been recently identified in
EVs isolated from non-activated PTEC culture super-
natants [32]. Furthermore, these three miRNA have
been previously identified with roles within renal
disease pathways. In rat cell lines and mouse models
miR-200a down-regulates TGF-β2, a central inducer
molecule in kidney fibrosis, and other molecules of
the fibrotic process including alpha smooth muscle
actin, fibronectin and collagen 1 [33]. Elevated levels
of this miRNA have been identified in patients with
hypertensive nephrosclerosis and the miRNA levels
correlated with proteinuria within this disease group
[34]. Thus, our findings of increased miR-200a from
exosomes derived from inflammatory PTEC could
potentially identify a specific in-vivo source for this
miRNA. MiR-222 has been implicated in lupus
nephritis pathology, with miR-222 in urinary sedi-
ment being inversely correlated with serum anti-
dsDNA level in patients with active lupus nephritis
[35]. MiR-204 was recently identified as one of seven
miRNA associated with progressive CKD [36] and it
has also been identified as one of three possible
urinary miRNA biomarkers for interstitial fibrosis/
tubular atrophy (IF/TA) in transplant patients [37].
There are no reports of the fifth miRNA, miR-4419a,
in kidney disease.
Of the two remaining miRNA species identified as
being significantly different between the exosomes pro-
duced from hypoxic versus normal PTEC, miR-3182
has been reported amongst the top 15 significantly up-
regulated miRNA in a study of renal cell carcinoma
[38]. Again miR-4448 has not been reported in the
kidney disease literature.
Of the three miRNA species identified as signifi-
cantly different between the hypoxia and inflammation
cultured PTEC, miR-375 has been implicated in renal
pathology [39], where it was identified as one of a
subset of cell-fraction miRNA in urine that was asso-
ciated with rejection of kidney allografts before any
histological evidence was detected. MiR-3613 has
Figure 7. Eleven out of 17 significantly differentially expressed exosomal proteins, derived from the hypoxic culture conditions
compared to the inflammation/normal culture condition groups, associate with a cellular assembly and organisation/cell morphol-
ogy pathway identified by the Networks function of IPA. Red colour indicates up-regulation and green colour indicates down-
regulation within the network and colour intensity indicates levels of regulation. Proteins highlighted in bold within the data table
are the 11 significantly differentially expressed exosomal proteins.
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been reported at significantly decreased expression
levels in urinary sediments of IgA nephropathy patients
with grade I-II and III disease [40]. This is somewhat at
odds with our findings that miR-3613 is elevated in
disease PTEC sample exosomes. However, other
reports have identified this miRNA as an important
down-regulator of the inflammatory response in other
organs, where it appears to function via two distinct
mechanisms: (i) degrading cytokine RNA and (ii) inhi-
biting the LPS/IL-1 NF kappa β signalling pathway
[41]. Our data would support these findings, extending,
for the first time, a role for miR-3613 to an anti-
inflammatory response in the kidney.
In line with other proteomic studies of exosomes, we
identified large numbers of peptides demonstrating
over five hundred different proteins were present
within our exosome populations. Of these, the largest
grouping (212) were expressed from exosomes across
all culture conditions. However, exosomes from all
three culture conditions produced proteins that were
unique to their specific culture conditions, representing
healthy (normal control conditions), early disease
(inflammatory disease conditions) and late disease
(hypoxic disease conditions). When we used IPA ana-
lysis to assign pathways to our proteins that were sig-
nificantly differentially expressed in our exosomes
from different culture conditions, as expected, we iden-
tified a range of pathways that were associated with the
inflammation/hypoxia process. Importantly however,
we also identified a number of renal related pathways
using both the “Disease and Biological Function” and
“Tox” clustering functions of IPA, providing a linkage
between proteins within PTEC exosomes and CKD.
Four of the significantly differentially expressed pro-
teins, complement C3 (C3), heparin sulphate proteo-
glycan core protein (HSPG2), tenascin (TNC) and
galectin-3 binding protein (GALS3BP) were present
across two or more culture conditions. C3 was signifi-
cantly down-regulated in the inflammation culture and
up-regulated in the hypoxia cultures compared to nor-
mal control culture. We and others have shown that
this molecule is produced by PTEC and its expression
level changes under perturbed conditions [17]. C3 is a
central player in both the classical and alternate com-
plement pathways and is also regarded as an inflam-
matory mediator. Gerritsma et al. have shown that C3
expression in human PTEC is up-regulated by the
inflammatory mediator IL-1α [42] and the breakdown
product of C3, C3a increases vascular permeability,
recruits neutrophils [43] and induces the respiratory
burst in these cells [44]. The increased expression of C3
within exosomes from our hypoxic PTEC may indicate
a mechanism by these cells to resolve the hypoxic
conditions by increasing vascular permeability and
recruiting neutrophils in an effort to degrade extracel-
lular matrix material induced by hypoxia. HSPG2 was
significantly increased within exosomes from both
inflammatory and hypoxic culture conditions. This
molecule plays a major role in both angiogenesis and
cell adhesion [45], two processes that require up-reg-
ulation to recover from an hypoxic environment,
where one sees decreasing oxygenation of the tissues
with subsequent cell detachment from basement mem-
branes. TNC is significantly up-regulated within exo-
somes from hypoxic conditions compared to both
normal and inflammation culture-derived exosomes.
TNC is an extracellular matrix protein which is closely
associated with the formation of stem cell niches
[46,47]. It is tempting to speculate that the increased
expression of this molecule within exosomes from
hypoxic PTEC cultures may be an effort to induce the
formation of stem cell niches within the tubulointer-
stitium, where mesenchymal tubular stem cells may
proliferate to replace cellular loss that occurs from
hypoxia in vivo. Finally, GALS3BP was also signifi-
cantly up-regulated in exosomes from hypoxic cultures
compared to both normal and inflammation cultures.
This molecule also plays a role in cellular adhesion [48]
and has been reported as an immune-stimulator/cellu-
lar defence protein [49], two biological processes one
would expect to be up-regulated within a hypoxic in
vivo environment. GALS3BP has previously been iden-
tified in urinary exosomes [50] and our findings would
identify PTEC as the primary source of these exosomes.
In conclusion, this study investigated, for the first
time, the production and molecular content of exo-
somes derived from primary human PTEC cultured
under normal and disease-related conditions. We
demonstrate a rapid reproducible methodology for
the purification of PTEC-derived exosomes, identi-
fied increased numbers of exosomes from disease-
state cultures and identified differential expressions
levels of both known and unique miRNA and protein
species from exosomes derived from different dis-
ease-culture conditions. The validity of this unbiased
approach is supported by the identification of
miRNA and protein pathways with known CKD
associations, providing a rationale to further evaluate
the known and novel miRNA and protein species
within PTEC-derived exosomes as targets for thera-
peutic intervention.
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